Recent Updates
Recently added Catalysts
SH

Scienture Holdings, Inc.

SCNXFDA catalysts, PDUFA dates & pipeline intelligence
$2.9
▼ -0.11 · -3.65%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full SCNX financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $2.6452W HIGH $18.75
Volume
4.58 K
Value Traded
13.37 K
Short % Float
9.17%
Days to Cover
3.1
-9.38%Week
-0.68%1 Month
-75.28%3 Month
-70.53%6 Month
-99.94%5 Year
-100%All Time

Cash Data

Unlock SCNX cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
5.12 M
EPS (TTM)
-23.11
P/E Ratio
-
Ent. Value
370.03 K
Total Shares
1.76 M
Float Shares
1.28 M
Insiders
22.08%
Institutions
5.26%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
NDA Submission
SCN-102
Migraine
NDASmall MoleculesNeurology
Unlock every SCNX catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

SCNX Catalyst Timeline

Dated clinical, regulatory and corporate events for Scienture Holdings, Inc.

Catalyst Timeline

Dated clinical, regulatory & corporate events for Scienture Holdings, Inc.

157Total events
8Upcoming
44Tier-1 (high impact)
2018 to 2028Coverage

Upcoming catalysts 2

T2Quarterly Update
Subscribe to view catalyst details
T2Quarterly Update
Subscribe to view catalyst details
REZENOPY™Approved

Event history 50

▲Reimbursement / PricingArbli™ApprovedPost-Market
Arbli added to formularies at three leading U.S. pediatric academic medical centers and hospitals
hypertensionsource ↗
▲Quarterly UpdateCorporate
Preliminary Q3 2026 revenue of ~$1.22M, up 256% sequentially
▲Partnership / LicenseREZENOPY™ApprovedCorporate
Scienture, LLC enters exclusive Sales, Marketing and Distribution Agreement with distribution partner for REZENOPY in addiction treatment centers
opioid overdosesource ↗
▲Product LaunchREZENOPY™ApprovedPost-Market
Commenced commercial launch of REZENOPY™
opioid overdosesource ↗
▲Patent GrantedREZENOPY™ApprovedIP / Competition
USPTO granted second patent covering REZENOPY™
opioid overdosesource ↗
▲Patent GrantedArbli™ApprovedIP / Competition
USPTO granted third patent covering Arbli™
hypertensionsource ↗
●Quarterly UpdateCorporate
Q2 2026 financial results reported
▲Product LaunchREZENOPY™ApprovedPost-Market
Commercial launch of REZENOPY™ and fulfillment of initial purchase orders
emergency treatment of known or suspected opioid overdosesource ↗
▲Product LaunchREZENOPY™ApprovedPost-Market
Commercial launch of REZENOPY (naloxone nasal spray 10 mg) in the U.S.
opioid overdosesource ↗
▲Product LaunchREZENOPY™ApprovedPost-Market
Successful commercial launch of REZENOPY (naloxone HCl) Nasal Spray 10 mg
Unlock the full SCNX catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How SCNX actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2025-03-13Arbli (losartan potassium) PDUFA Date ApprovedPDUFA
Unlock 2 more SCNX historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Unlock the SCNX pipeline intelligence model
Every scored asset with PTRS, rNPV, enrollment velocity and trial design quality.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every SCNX program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
Scroll for more · summaries link to the source press release
Unlock every SCNX trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock SCNX insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Shankar HariharanDirector, Officer (Co-CEO & Chairman), 10% OwnerAcquisition 500,000 3,518,679 held$0.00 02/20/2026
Unlock the full SCNX insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
No hedge fund reported a 13F position in SCNX for Q2 2026.
Unlock every fund holding SCNX
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in SCNX
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see SCNX ownership
Insider and institutional ownership, quarter by quarter.

SCNX Short Interest

Shares sold short, counted twice a month.

9.17%
Short % of Float
of tradable shares sold short
117.3K
Shares Sold Short
+10.9% vs prior count
3.1 Moderate
Days to Cover
trading days of normal volume to buy every short share back
37.4K
Avg Daily Volume
the average used for days to cover
Unlock SCNX short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock SCNX option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live SCNX option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock SCNX options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How SCNX ranks across every disease it competes in

Competitive Position is a premium feature
See how SCNX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

SCNX News

-SCNX
Nov 16, 2026
SCNXGeneral
▼ -3.6%today

SCIENTURE Reports Q3 2026 Results with Approximately 265% Sequential Revenue Growth Driven by the Commercial Launch of REZENOPY™

Scienture Holdings reported a robust Q3 2026 with a 265% sequential revenue growth, reaching $1.25 million. The commercial launch of REZENOPY™ contributed significantly, generating approximately $925,000 in initial sales. Gross profit also saw a notable increase of 77.5% year-over-year. Despite these gains, the company reported a net loss of approximately $6.0 million for the quarter.

Read more →
-SCNX
Oct 22, 2026
SCNXGeneral

SCIENTURE Issues Shareholder Letter Highlighting Sequential Revenue Growth, Two FDA-Approved Commercial Products, and Continued Progress Toward Profitability in 2027

Scienture Holdings reported preliminary third-quarter 2026 revenue of $1.22 million, a 256% sequential increase. The growth followed the August commercial launch of REZENOPY™ and a 74% rise in Arbli™ wholesale unit sales. The company targets profitability in 2027 using its high gross margins and established commercial infrastructure.

Read more →
-SCNX
Oct 13, 2026
SCNXGeneral
▼ -17.1%on this news

SCIENTURE Reports Approximately $1.22 Million in Unaudited Preliminary Q3 2026 Revenue, Achieving 256% Sequential Growth

Scienture Holdings, Inc. reported preliminary Q3 2026 revenue of approximately $1.22 million, marking a 256% increase from the previous quarter. This growth is attributed to the successful launch of REZENOPY and increased sales of Arbli. The company aims to expand its pharmaceutical portfolio and achieve profitability by 2027.

Read more →
-SCNX
Oct 2, 2026
SCNXGeneral
▼ -10.3%on this news

SCIENTURE Announces Arbli™ Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and Hospitals

Scienture Holdings, Inc. announced that its product Arbli™ has been added to the formularies of three prominent U.S. pediatric academic medical centers. This addition marks a significant milestone in expanding Arbli™'s market presence, particularly in pediatric care. The product, a proprietary oral suspension of losartan potassium, aims to improve patient access and compliance. Scienture anticipates continued growth driven by increasing wholesale orders and institutional adoption.

Read more →
-SCNX
Sep 30, 2026
SCNXGeneral
▼ -31.8%on this news· ran to -42% by day 3shared move

Scienture Holdings, Inc. Announces Reverse Stock Split

Scienture Holdings, Inc. announced a 1-for-25 reverse stock split effective October 5, 2026. This move aims to comply with Nasdaq's minimum bid price requirement and facilitate future share issuance. Post-split, the company will have approximately 1.64 million shares outstanding, with no change in par value or authorized shares.

Read more →
-SCNX
Sep 22, 2026
SCNXGeneral
▼ -6.4%on this news

SCIENTURE Expands Commercial Reach of REZENOPY™ to Addiction Treatment Centers through an Agreement with a Distribution Partner

Scienture Holdings, Inc. has announced an exclusive agreement to distribute REZENOPY™ through a partner network of approximately 2,000 opioid treatment clinics in the U.S. This partnership aims to enhance the availability of naloxone, a critical treatment for opioid overdoses. The agreement aligns with Scienture's broader commercialization strategy and is expected to significantly contribute to REZENOPY™'s revenue growth.

Read more →
-SCNX
Sep 9, 2026
SCNXConferences/Events

SCIENTURE to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026

Scienture Holdings, Inc. will present at the H.C. Wainwright 28th Annual Global Investment Conference from September 14-16, 2026. The company plans to showcase its commercial momentum, particularly the growing adoption of Arbli™ and the recent launch of REZENOPY™. Management anticipates significant revenue growth driven by these products and aims for profitability by 2027.

Read more →
-SCNX
Aug 14, 2026
SCNXGeneral

SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance

Scienture Holdings, Inc. reported significant financial improvements for Q2 2026, including a 510% increase in revenue compared to Q1 2026. The company's gross margin was approximately 97.7%, and both operating and net losses narrowed significantly year-over-year. The commercial launch of REZENOPY™ marks an expansion of their product portfolio, indicating a positive trajectory for future growth.

Read more →
-SCNX
Aug 12, 2026
SCNXGeneral
▲ +10%on this newsshared move

SCIENTURE Announces Commercial Launch and Fulfillment of Initial Purchase Orders of REZENOPY™, the Highest Dose FDA-Approved Naloxone Nasal Spray

Scienture Holdings, Inc. has announced the commercial launch of REZENOPY™, the highest-dose FDA-approved naloxone nasal spray. The product is designed for emergency treatment of opioid overdoses and has begun nationwide distribution following the fulfillment of initial purchase orders. Scienture aims to expand market access and adoption through a dedicated sales team and payer coverage.

Read more →
-SCNX
Jul 9, 2026
SCNXFDA Updates

SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY™ (naloxone hydrochloride) to Wholesalers

Scienture Holdings, Inc. announced the completion of manufacturing and upcoming shipments of REZENOPY™ (naloxone hydrochloride) Nasal Spray 10 mg to U.S. wholesalers, with commercial availability expected in August. This product is designed for emergency treatment of opioid overdoses and represents a significant opportunity in the $144 million naloxone market. The company has also expanded payer access to over 100 million lives, enhancing its market position.

Read more →
-SCNX
Jun 18, 2026
SCNXGeneral

SCIENTURE Expands Arbli™ Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide

Scienture Holdings, Inc. has announced significant advancements in the commercialization of Arbli™, including expanded payor coverage that now includes approximately 12.5 million additional covered lives. The company is focusing on increasing patient access through broader pharmacy networks and channel partnerships. Arbli™, a liquid formulation of losartan, aims to improve compliance among patients who have difficulty swallowing tablets.

Read more →
-SCNX
Jun 9, 2026
SCNXFDA Updates

SCIENTURE Secures Formulary Coverage for REZENOPY™ with a Large National Health Plan and Expands Commercial Team

Scienture Holdings, Inc. announced that its naloxone product, REZENOPY™, has been added to the formulary of a large national health plan, enhancing access for over 100 million covered lives. The product, which is the highest FDA-approved naloxone dose available, is set for commercial launch in mid-July 2026. Scienture is also expanding its sales team to support the product's rollout across various healthcare sectors.

Read more →
-SCNX
Jun 2, 2026
SCNXFDA Updates

SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041

Scienture Holdings, Inc. announced the granting of U.S. Patent No. 12,622,903 B2 for REZENOPY™ (naloxone HCl) Nasal Spray 10 mg, effective May 12, 2026, expiring February 5, 2041. This patent strengthens their intellectual property and supports their exclusive commercialization rights in the U.S. The product, approved by the FDA, aims to address the opioid overdose crisis.

Read more →
-SCNX
May 18, 2026
SCNXGeneral

SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion

Scienture Holdings, Inc. reported significant financial growth for Q1 2026, with revenue increasing by 449% year-over-year to approximately $56,000. The gross profit surged by 7900%, leading to a gross margin expansion to 95.6%. The company also secured key patents and financing to support its product portfolio and commercialization strategy. However, it reported a net loss of approximately $3.4 million.

Read more →
-SCNX
May 7, 2026
SCNXGeneral
▲ +8.6%on this news

Scienture Secures $11.0 Million in Non-Dilutive Debt Financing to Accelerate Growth of Approved Product Portfolio and Advancement of R&D Pipeline

Scienture Holdings has secured $11 million in non-dilutive debt financing to enhance its commercial efforts for its FDA-approved products, Arbli™ and REZENOPY™. The funds will also support the advancement of its R&D pipeline, which includes multiple therapeutic candidates. Company executives expressed confidence that this financing would help the company achieve profitability by 2027 and mentioned a focus on operational milestones. This strategic funding marks a significant step in the company's growth trajectory and commitment to patient care.

Read more →
-SCNX
May 6, 2026
SCNXGeneral

SCIENTURE Announces Third Patent Grant for ARBLI™ (losartan potassium) Oral Suspension, Strengthening Long-Term Market Exclusivity Through 2041

Scienture Holdings, Inc. announced the granting of a third patent for ARBLI™, its FDA-approved losartan potassium oral suspension. This patent, issued on April 21, 2026, extends intellectual property protection until October 2041. ARBLI™ offers a ready-to-use liquid formulation, enhancing patient compliance, particularly for those unable to swallow tablets. The product is positioned to capture significant market share in the $241 million U.S. losartan market.

Read more →
-SCNX
Apr 15, 2026
SCNXGeneral
▲ +16.7%on this news

Scienture Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

Scienture Holdings, Inc. has been granted a 180-day extension by Nasdaq to meet the minimum bid price requirement of $1.00 per share. The company has until October 12, 2026, to achieve compliance. Scienture highlights its potential for growth with the upcoming launch of Arbli™, a novel FDA-approved hypertension treatment, and REZENOPY™, a naloxone nasal spray. However, the company acknowledges challenges in maintaining Nasdaq compliance standards.

Read more →
-SCNX
Apr 6, 2026
SCNXGeneral
▲ +10.3%on this news

Scienture Provides Annual Shareholder Update, Outlining Significant Progress and Strategic Priorities for the Year Ahead

Scienture Holdings, Inc. provided a comprehensive annual update highlighting significant progress in its pharmaceutical platform. Key achievements include the successful launch of Arbli™, an FDA-approved liquid formulation of losartan, and the strategic acquisition of REZENOPY™, aimed at addressing opioid overdose. The company reported a 216% increase in net revenue year-over-year, despite a net loss due to a one-time impairment charge. Looking ahead, Scienture is focused on expanding its commercial portfolio and advancing its R&D pipeline.

Read more →
-SCNX
Mar 30, 2026
SCNXGeneral
▼ -42.2%on this news

SCIENTURE Reports Year End 2025 Financial Results and Provides Business Update

Scienture Holdings, Inc. reported a remarkable 216% increase in net revenue for the year ending December 31, 2025, reaching $431,609. The company also achieved a gross margin expansion to 76.8% and improved its operational efficiency. Key developments included the successful launch of Arbli™, which has gained significant traction in the market, and strategic collaborations to enhance access to its products. Despite a net loss attributed to a one-time impairment charge, the company is optimistic about its growth momentum into 2026.

Read more →
-SCNX
Mar 11, 2026
SCNXGeneral
▲ +19.5%on this news

SCIENTURE Broadens Commercial Access for REZENOPY™, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions

Scienture Holdings, Inc. has announced the formalization of multiple Group Purchasing Organization (GPO) agreements for its FDA-approved naloxone nasal spray, REZENOPY™, increasing its access to over 5000 healthcare institutions in the U.S. This move is expected to enhance the product's adoption, leveraging the significant commercial opportunity presented by the naloxone market, which totals approximately $141 million annually. REZENOPY™ is positioned as the highest-dose naloxone formulation approved by the FDA and aims to address opioid overdose emergencies across various healthcare settings.

Read more →

About Scienture Holdings, Inc.

Commack, NY 9 employees scienture.com
Headquarters20 AUSTIN BLVD., COMMACK, NY, 11725
BIOPHARMAWATCH ELITE
Trade the next SCNX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime